echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The prospect of drugs for rare diseases is promising, a pharmaceutical enterprise invests 20 million US dollars into the Bureau

    The prospect of drugs for rare diseases is promising, a pharmaceutical enterprise invests 20 million US dollars into the Bureau

    • Last Update: 2020-02-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [pharmaceutical network market analysis] on February 18, Wuxi apptec announced that eight investors, including Wuxi fund phase I, general Atlantic, a wholly-owned subsidiary of the company, signed a subscription agreement for preferred shares with Beihai Kangcheng and other interested parties It is proposed to subscribe 1692100 preferred shares newly issued by Beihai Kangcheng, with a subscription amount of US $20 million It is understood that Beihai Kangcheng and its subsidiaries, founded in 2012, are innovative platform pharmaceutical technology companies focusing on rare disease drugs, with multiple pipelines for rare disease products There are also two cancer products, CommScope ® and naratinib, which have been launched in mainland China and Hong Kong, respectively Another hunterase ® product for treating Hunt syndrome is in the stage of new drug approval The rare disease, also known as "orphan disease", refers to a rare disease that occurs only in a very small number of people At present, there are more than 7000 rare diseases that have been identified It is estimated that there are more than 300 million patients with rare diseases worldwide, accounting for 1 / 15 of the global population About half of the patients with rare diseases are children, and about 30% of children with rare diseases die before the age of 5 At present, there are more than 16.8 million patients with rare diseases in China In recent years, with the increase of population, the number of patients with rare diseases is also increasing, and the demand for drugs is also increasing Therefore, under the influence of many factors, the research and development of drugs for rare diseases has gradually become the main battlefield of new drug research and development Data shows that in 2018, the global market size of rare disease drugs was US $131 billion, with a compound annual growth rate of 12.3% It is estimated that by 2024, the market size of rare disease drugs will reach US $242 billion The growth rate of rare disease drug market is twice that of non rare disease drug market in the same period (6%) It is estimated that by 2024, the proportion of rare disease drug in prescription drug market will exceed 20% At present, more and more large pharmaceutical companies, such as Novartis, Baijian, Roche, Pfizer, semefei and cro, are expanding or introducing their business segments in gene therapy through M & A, or in-depth cooperation with gene therapy pharmaceutical companies, so as to ensure their competitiveness in the field of rare disease treatment by mastering core technology and production capacity In recent years, China has paid more attention to the rare disease population For example, in terms of policy, in January last year, the state decided to give value-added tax preference to rare disease treatment drugs From March 1, for the first batch of 21 rare disease drugs and 4 APIs, the import value-added tax will be reduced by 3% with reference to anti-cancer drugs For domestic links, the value-added tax can be calculated by 3% simple method With the introduction of favorable policies in China, the diagnosis, treatment and drug research and development of rare diseases in China are gradually on the right track, and many foreign drugs are also entering the Chinese market, with increasingly fierce competition However, in fact, there are many R & D pipelines and strong strength of multinational pharmaceutical enterprises, and the competitiveness of domestic enterprises in this field is still slightly insufficient for the time being As practitioners, how to choose the research and development field of rare diseases in the future, and how to formulate the corresponding research and development strategies are the first issues to be pondered by relevant domestic pharmaceutical companies.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.